Australians 65 and older first to access influenza vaccine - FLUAD® Quad
Seqirus Australia welcomes the listing of FLUAD® Quad (Inactivated Quadrivalent Influenza Vaccine (Surface Antigen), Adjuvanted) on the 2020 National Immunisation Program (NIP), for adults aged 65 and older.
Australia is the first country in the world to offer FLUAD® Quad vaccine.
FLUAD® Quad is a four strain (quadrivalent) inactivated flu vaccine that works by causing your body to produce its own antibodies against the four types of influenza virus that are in the vaccine. FLUAD® Quad also contains an adjuvant, a substance added to the vaccine to facilitate the process.
Adjuvanted vaccines are sometimes used for older adults as the effectiveness of the immune system decreases with age.
Influenza can have a substantial negative impact on adults 65 years and older with higher hospitalisation and death rates compared to younger, healthier adults. Between 1997 and 2016, 80 per cent of influenza reported deaths in Australia were in people aged 65 and over.
Associate Professor Woodward AM, Director, Aged Care Research and the Head of Memory Clinic at Austin Health said that this is not the year you want to get flu, nor be complacent about the significant impact influenza has each year on our public health system, particularly the more severe cases that end up in intensive care units (ICU).
“Vaccinating for flu is always important – but this year it will be particularly critical, and especially for older Australians and those with chronic diseases.
“While the flu vaccine does not protect against the COVID-19 virus, immunising against the flu - particularly in high-risk groups like those aged 65 and over – may help to reduce the risk of diagnostic uncertainty between flu and COVID-19 and reduce pressure on our health system and ICUs.”
Seqirus Asia Pacific Head of Medical Affairs, Dr Jonathan Anderson congratulated the Federal Government and Minister Hunt for fast tracking the approval of FLUAD® Quad for delivery via the NIP for Australians aged 65 and over in advance of the 2020 influenza season.”
Seqirus, a CSL company, is Australian owned, operating Australia’s only onshore influenza vaccine manufacturing site.
The most commonly reported side-effects of FLUAD® Quad can be pain around the injection site, fatigue and headache. These tended to be mild to moderate and resolved within 3 days.
Please speak with your healthcare professional if you have any questions about flu vaccination, including whether it is suitable for you.
PBS Information: FLUAD® Quad is listed on the National Immunisation Program (NIP) Schedule – https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule#flu-influenza-vaccines
Watch Associate Professor Michael Woodward AM, Director, Aged Care Research and the Head of Memory at Austin Health and other experts speak about FLUAD® Quad vaccine (12 minutes) at https://senateshj.digitalpigeon.com/shr/NrgvEHM2Eeq8owb4tvG4vQ/0_qeKLji12Dr6tCQXvxg9A
1 April 2020.